Pharmaceutical

The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells. Primary challenge in selectively targeting cancer cells is to differentiate between the cancer cells and the normal cells. One such difference is enzyme telomerase activity which has been an exciting drug target as it is active in almost 85—90% of all human cancers but is inactive in normal human cells. Telomerase is a ribonucleoprotein that synthesizes telomeres. The increase in the activity of telomerase is seen very early during tumorigenesis and techniques such as the telomeric repeat amplification protocol (TRAP) assay have been useful in meas...